Imene Zerizer

Imene Zerizer

Auto-generated profile, based on publicly available information

Imene Zerizer

Dartford and Gravesham NHS Trust, Dartford, Kent, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Clinical Imaging
Verified
Journal Article
Closed access
APArman Parsai
Arman Parsai
MMMarc Miquel
Marc Miquel
HJHikmat Jan
Hikmat Jan
AKAdrian Kastler
Adrian Kastler
TSTeresa Szyszko
Teresa Szyszko
IZImene Zerizer
Imene Zerizer

1 March 2015 in Clinical Imaging
Verified
Journal Article
Closed access
APArman Parsai
Arman Parsai
IZImene Zerizer
Imene Zerizer
OROran Roche
Oran Roche
PGPanos Gkoutzios
Panos Gkoutzios
MMMarc Miquel
Marc Miquel

1 September 2011 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
KWKa Kit Wong
Ka Kit Wong
MAMohammad Arabi
Mohammad Arabi
IZImene Zerizer
Imene Zerizer
AAAdil Al-Nahhas
Adil Al-Nahhas
DRDomenico Rubello
Domenico Rubello
MGMilton D. Gross
Milton D. Gross
Positron emission tomography (PET) has seen an increasing clinical utilization in the last decade, such that it is now a standard oncology imaging modality. Its success is based on the detection of altered fluorine-18 fluorodeoxyglucose (18F-FDG) biodistribution, reflecting glucose transport/metabolism in malignant tumor tissues. Integrated PET/computed tomography cameras combine functional and anatomical information in a synergistic manner that improves diagnostic interpretation, and newer positron-emitting radiopharmaceuticals have been developed to expand the application of non-FDG PET imaging. The increasing use of cross-sectional imaging procedures has led to a more frequent detection of incidental adrenal masses. Although conventional imaging modalities such as computed tomography and MRI can characterize the majority of these lesions, 18F-FDG PET has been reported as a useful tool to distinguish benign from malignant etiologies in indeterminate adrenal masses. Although 18F-FDG PET has enjoyed success in staging a wide range of cancers, including detection of adrenal metastases and evaluation of adrenocortical carcinoma, it has had limited impact for the evaluation of neuroendocrine tumors. Positron-emitting amine precursor and somatostatin analogs have been validated in research settings to provide accurate imaging of enterochromaffin and chromaffin neuroendocrine tumors and medullary thyroid cancer. The aim of this review article is to provide an overview of the role of 18F-FDG and newer positron-emitting radiopharmaceuticals in the evaluation of adrenal and neuroendocrine tumors.

23 May 2025 in Clinical Nuclear Medicine Open
Verified
Journal Article
Open access
APArman Parsai
Arman Parsai
IZImene Msc Zerizer
Imene Msc Zerizer
HJHikmat Jan
Hikmat Jan
AKAdrian Kastler
Adrian Kastler
EMEushaa Msc Mirza
Eushaa Msc Mirza
MMMarc Miquel
Marc Miquel
Objective: MRI is the preferred spinal imaging modality, but lacks metabolic information, while SPECT/CT provides functional information on osteoblastic activity. We aimed to determine if retrospective fusion of SPECT and MRI (SPECT/MRI) enhances disease site identification and reader confidence compared with SPECT/CT or MRI in chronic back pain refractory to medical management. Methods: One hundred and eighteen patients with chronic back pain not responding to medical management and investigated with MRI and SPECT/CT were selected. Two readers compared SPECT/MRI images to sequential reviews of SPECT/CT and MRI, MRI, and SPECT/CT alone. Potential pain generator sites and diagnostic confidence for each modality were recorded. New findings on SPECT/MRI were reviewed at a multidisciplinary meeting (MDM), and potential management changes were recorded. Results: Diagnostic confidence for SPECT/MRI (4.99) was higher than sequential SPECT/CT and MRI (3.8), MRI (3.6), or SPECT/CT (3). SPECT/MRI did not detect new disc disease, but found more sites (1%) in patients with known disc disease compared with other modalities. SPECT/MRI detected more patients and sites of endplate and facet disease compared with other modalities. It found 25% more patients and 49.5% more sites for endplate disease; 31.3% more patients and 46.7% more sites for facet disease compared with sequential review of SPECT/CT and MRI. The MDM review did not change the management for new disc disease sites. However, in 19 (25.6%) patients with new endplate disease, 45 (38.1%) patients with additional endplate disease, 20 (16.9%) patients with new facet disease, and 45 (38.1%) patients with additional facet disease, management changes were adopted. Conclusions: SPECT/MRI in refractory back pain detects additional disc, endplate, and facet disease sites and new patients compared with sequential SPECT/CT, MRI, or SPECT/CT alone, potentially leading to management changes.